{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:40:57Z","timestamp":1791330057495,"version":"4.3.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:00:00Z","timestamp":1760227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["227516\/Z\/23\/Z"],"award-info":[{"award-number":["227516\/Z\/23\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinme.2025.100522","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T16:14:00Z","timestamp":1760804040000},"page":"100522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hepatitis C: current treatments, emerging therapies and tackling health inequities on the path to global elimination"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-9692","authenticated-orcid":false,"given":"Hamzah Z.","family":"Farooq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clinme.2025.100522_bib0001","doi-asserted-by":"crossref","first-page":"ofaa317","DOI":"10.1093\/ofid\/ofaa317","article-title":"Clinical and patient-reported outcomes of direct-acting antivirals for the treatment of chronic Hepatitis C among patients on opioid agonist treatment: a real-world prospective cohort study","volume":"7","author":"Schulte","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clinme.2025.100522_bib0002","unstructured":"WHO. Global hepatitis report 2024; action for access in low- and middle-income countries. In: Global HIV HaSPH, Health Product Policy and Standards (HPS), editor. Geneva: WHO; 2024."},{"issue":"6","key":"10.1016\/j.clinme.2025.100522_bib0003","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinme.2025.100522_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2458-14-3","article-title":"Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection?","volume":"14","author":"Schmidt","year":"2014","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.clinme.2025.100522_bib0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clinme.2025.100522_bib0006","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/gutjnl-2024-332177","article-title":"Unusual\u2019 HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment","volume":"73","author":"Vo-Quang","year":"2024","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.clinme.2025.100522_bib0007","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2893.2009.01087.x","article-title":"Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis","volume":"16","author":"Castera","year":"2009","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.clinme.2025.100522_bib0008","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S2468-1253(22)00355-7","article-title":"A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia","volume":"8","author":"Grebely","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinme.2025.100522_bib0009","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.08.059","article-title":"Improving uptake of hepatitis B and hepatitis C testing in South Asian migrants in community and faith settings using educational interventions\u2013a prospective descriptive study","volume":"100","author":"Kelly","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.clinme.2025.100522_bib0010","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2893.2011.01552.x","article-title":"Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations","volume":"19","author":"Jacobson","year":"2012","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.clinme.2025.100522_bib0011","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"Singal","year":"2020","journal-title":"J Hepatol"},{"issue":"9956","key":"10.1016\/j.clinme.2025.100522_bib0012","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"9954","key":"10.1016\/j.clinme.2025.100522_bib0013","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clinme.2025.100522_bib0014","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"60","author":"Mutimer","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinme.2025.100522_bib0015","unstructured":"Chief Medical Officer\u2019s Annual Report (2021): Health in Coastal Communities. Department of Health and Social Care. Published: 21st July 2021. URL link: https:\/\/www.gov.uk\/government\/publications\/chief-medical-officers-annual-report-2021-health-in-coastal-communities."},{"key":"10.1016\/j.clinme.2025.100522_bib0016","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S0168-8278(25)00417-9","article-title":"OS-102 mortality benefits of a national program of supported, active care in the treatment of marginalised people with chronic HCV infection","volume":"82","author":"Simmons","year":"2025","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.clinme.2025.100522_bib0017","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14787210.2023.2255751","article-title":"Is the UK set to be hepatitis C free?","volume":"22","author":"Guerra-Veloz","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7","key":"10.1016\/j.clinme.2025.100522_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.1870","article-title":"Health and economic impact of periodic hepatitis C virus testing among people who inject drugs","volume":"6","author":"Zhu","year":"2025","journal-title":"JAMA Health Forum"},{"issue":"10","key":"10.1016\/j.clinme.2025.100522_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003818","article-title":"Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: a modelling study and economic analysis","volume":"18","author":"Lim","year":"2021","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.clinme.2025.100522_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41541-023-00635-9","article-title":"Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity","volume":"8","author":"Patra","year":"2023","journal-title":"npj Vaccines"},{"issue":"4","key":"10.1016\/j.clinme.2025.100522_bib0021","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/cid\/ciac820","article-title":"A systematic review of human challenge trials, designs, and safety","volume":"76","author":"Adams-Phipps","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211825002404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211825002404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:50:17Z","timestamp":1773309017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211825002404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1470211825002404"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2025.100522","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C: current treatments, emerging therapies and tackling health inequities on the path to global elimination","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2025.100522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100522"}}